Objective To explore the effect of vascular endothelial growth factor-C (VEGF-C) gene transfection on the expression level of VEGF-C in human breast cancer MCF-7 cell. Methods The constructed VEGF-C gene eukaryotic expression vector was transfected into the human breast cancer MCF-7 cell by using lipofectamine transfection reagents， and the positive cell clones were obtained through G418 selection after transfection. The expressions of VEGF-C mRNA and protein were detected by RT-PCR and Western blot respectively. Results Following the transfection of the VEGF-C recombination plasmid, there were significant differences on the expression levels of VEGF-C mRNA and protein between pcDNA3.1-VEGF-C transfection group and pcDNA3.1 transfection group （12.382±2.183 vs 6.039±1.950, P＜0.01; 0.971±0.186 vs 0.594±0.196, P＜0.05). Conclusion With the transfection of pcDNA3.1-VEGF-C vector by using the liposome, the expression levels of VEGF-C mRNA and protein rise up in breast cancer MCF-7 cell.
目的:探討前列倍喜膠囊加а受體阻滯劑(naftopidil)治療慢性前列腺炎/慢性骨盆疼痛綜合征(CP/CPPS)的臨床療效。方法:按前列腺炎診斷治療指南標準［1］選出符合CP/CPPS患者96例,采用隨機雙盲對照,分為治療組和對照組。治療組(56例)服用前列倍喜膠囊加а-受體阻滯劑;對照組(40例)服用а-受體阻滯劑加安慰劑;療程為6周。配合前列腺按摩,每周一次,然后觀察其療效。結果:治療組56例患者,顯效16例,有效34例,無效6例。總有效率89.3%(50/56);對照組40例患者,顯效4例,有效24例,無效12例。總有效率70.0%(28/40)。兩組療效比較有統計學意義(Plt;0.05);治療組治療前后NIH-CPSI各項指標比較有顯著性統計學意義(Plt;0.01);對照組治療前后NIH-CPSI各項指標比較有統計學意義(Plt;0.05),兩組治療前后NIH-CPSI比較有統計學意義(Plt;0.05)。結論:前列倍喜膠囊加а-受體阻滯劑聯合治療CP/CPPS安全有效。